Medical and Pharmaceutical Phase Scientific International advances urine biopsy tech with $34M fundraising round The company has gained strong market traction by launching over 30 diagnostic products across multiple health categories Joseph Morton3 days ago
Medical and Pharmaceutical Breath tests could soon become key diagnosis tool for multiple diseases Researchers are working to bring this technology to market Joseph MortonMay 14, 2025
Medical and Pharmaceutical Soleno Therapeutics pulls in FDA nod for treatment for rare genetic disease This approval is a hard-won victory for Soleno after a lengthy clinical trial phase Joseph MortonMarch 27, 2025
Medical and Pharmaceutical Is Cardiff Oncology 15% bump due to positive clinical trials or a short squeeze? Individual biotech stocks often decouple from macro trends when company developments or investor enthusiasm take center stage Joseph MortonMarch 12, 2025
Medical and Pharmaceutical TG Therapeutics stock spikes on strong financials and optimism for its flagship drug The company's product for relapsing forms of multiple sclerosis (RMS), is its primary source of its most recent success Joseph MortonMarch 3, 2025
Medical and Pharmaceutical Sana Biotechnology could offer relief to diabetes type 1 sufferers in the future The study showed that Sana's hypoimmune (HIP) modified pancreatic islet cells could successfully evade the patient's immune system Joseph MortonJanuary 9, 2025
Medical and Pharmaceutical RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement The biotech operator can develop and commercialize Jemincare's food allergy medication throughout most of the world Rowan DunneDecember 23, 2024
Health & Wellness Personalis Inc share price jumps 50% on deals with Merck and Moderna These developments are a validation of Personalis' business strategy and its potential in the genomics and cancer treatment space Joseph MortonDecember 19, 2024
Medical and Pharmaceutical Krystal Biotech reports success with inhalable lung cancer drug in early-stage trial KB707 demonstrated a 27% objective response rate and 73% disease control rate Rowan DunneDecember 19, 2024
Medical and Pharmaceutical Portage Biotech soars after initiating proceedings for iOx Therapeutics sale The stock went up by over 185% after the LOI was announced Rowan DunneDecember 17, 2024